Abstract
Although interferon (IFN)-α has no specific inhibitory effect on the plating efficiency of granulocyte-macrophage colony- forming cells (CFU-GM) from patients with chronic myeloid leukaemia (CML), it does selectively inhibit the replating ability (secondary colony formation) of CML CFU-GM. Thus, amplification of CFU-GM may be a target for IFN-α and other agents used in the treatment of CML. Here we examined whether cytarabine (Ara-C) or all-trans retinoic acid (ATRA) exert similar effects and whether they might in combination with IFN-α enhance its efficacy. We found that Ara-C preferentially inhibits the formation of CML CFU-GM compared to normal CFU-GM, but this inhibition was not increased by addition of IFN-α. When Ara-C was added to cultures containing IFN-α, the inhibition of replating by CML progenitors was abrogated. ATRA increased significantly the plating efficiency of normal CFU-GM. The addition of IFN-α to ATRA had no effect on CML or normal colony numbers. However, addition of ATRA to cultures containing IFN-α reversed the selective inhibition of CML CFU-GM replating seen in cultures containing IFN-α alone. In four IFN-α/Ara-C experiments, secondary CML patient-derived colonies were examined by fluorescence in situ hybridisation (FISH). All of them were Ph chromosome positive. No significant effects on CFU-GM production were observed when CML primitive haemopoietic progenitor cells were investigated in a delta (Δ) assay. Thus we conclude that combining IFN-α with Ara-C or ATRA neutralises the effect of IFN-α on CML CFU-GM. This observation provides a rationale for treating patients with alternating courses of IFN-α and Ara-C or ATRA, rather than giving either of these two agents in combination with IFN-α.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Gordon MY, Goldman JM . Cellular and molecular mechanisms in chronic myeloid leukaemia: biology and treatment Br J Haematol 1996 95: 10–20
Gordon MY, Dazzi F, Marley SB, Lewis JL, Nguyen D, Grand FH, Davidson RJ, Goldman JM . Cell biology of CML cells Leukemia 1999 13: (Suppl. 1) S65–S71
Talpaz M, Kantarjian HM, McCredie K, Trujillo JM, Keating MS, Gutterman JU . Haematologic remission and cytogenetic improvement induced by recombinant human interferon alfa in chronic myelogenous leukemia New Engl J Med 1986 314: 1065–1069
Talpaz M, Kantarjian H, Kurzrock R, Trujillo JM, Gutterman JU . Interferon-alfa produces sustained cytogenetic responses in chronic myelogenous leukemia: Philadelphia chromosome-positive patients Ann Intern Med 1991 114: 532–538
The Italian Cooperative Study Group on Chronic Myeloid Leukemia . Interferon-alpha-2a as compared with conventional chemotherapy for the treatment of chronic myeloid leukemia New Engl J Med 1994 330: 820–825
Allen NC, Richards SM, Shepherd PCA . UK Medical Research Council randomised, multicentre trial of interferon-α in chronic myeloid leukaemia: improved survival irrespective of cytogenetic response Lancet 1995 345: 1392–1397
Ohnishi K, Ohno R, Tomonaga M, Kamada N, Onozawa K, Kuramoto A, Dohy H, Mizoguchi H, Miyawake S, Tsubaki T, Miura Y, Omine M, Kobayashi T, Naoe T, Ohshima T, Hirashimi K, Ohtake S, Takahashi I, Morishima Y, Naito K, Asou N, Tanimoto M, Sakuma A, Yamada K, and the Kousheisho Leukemia Study Group . A randomized trial comparing interferon with busulphan for newly diagnosed chronic myelogenous leukemia in chronic phase Blood 1995 86: 906–919
Dowding C, Guo A-P, Maisin D, Gordon MY, Goldman JM . The effects of interferon-α on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint Br J Haematol 1991 77: 165–171
Galvani D, Cawley JC . Mechanism of action of α-interferon in chronic granulocytic leukaemia: evidence for preferential inhibition of late progenitors Br J Haematol 1989 73: 475–479
Olidapu-Williams C, Svet-Moldavaskaya I, Vilcek J, Ohnuma T, Holland J . Inhibitory effects of human leukocyte and fibroblast interferons on normal and chronic myelogenous leukemic granulocytic progenitor cells Oncology 1981 338: 356–360
Gordon MY, Marley SB, Lewis JL, Davidson RJ, Nguyen DX, Grand FH, Amos TAS, Goldman JM . Treatment with interferon-α preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia but spares normal CFU-GM J Clin Invest 1998 102: 710–715
Marley SB, Deininger MWN, Davidson RJ, Goldman JM, Gordon MY . The tyrosine kinase inhibitor STI571, like interferon alfa, preferentially reduces the capacity for amplification of granulocyte^macrophage progenitors (CFU-GM) from patients with chronic myeloid leukemia Exp Hematol (in press)
Stryckmans PA, Debusscher L, Collard E . Cell kinetics in chronic granulocytic leukemia (CGL) Clin Haematol 1977 6: 21–40
Eaves CJ, Eaves AC . Stem cell kinetics Bailliere's Clin Haematol 1997 10: 233–257
Sokal JE, Leong SS, Gomez GA . Preferential inhibition by cytarabine of CFU-GM from patients with chronic granulocytic leukemia Cancer 1987 59: 197–202
Sokal JE, Gockerman JP, Bigner SH . Evidence for a selective antileukemic effect in chronic granulocytic leukemia Leukemia Res 1988 12: 453–458
Guilhot F, Chastang C, Michallet M, Guerci A, Haroussea J-L, Maloisel F, Bouabdallah R, Guyatot D, Cheron N, Nicolini F, Abgrali J-F, Tanzer J, for the French Chronic Myeloid Leukemia Study Group . Interferon alfa-2b combined with cytarabine vs interferon alone in chronic myelogenous leukemia New Engl J Med 1997 337: 223–229
Mahon FX, Chahine H, Barbot C, Pigonnier V, Jazwiec B, Reiffers J, Ripoche J . All-trans retinoic acid potentiates the inhibitory effects of interferon-α on chronic myeloid leukemia progenitors in vitro Leukemia 1997 11: 667–673
Zheng A, Savolainen E-V, Koistinen P . All-trans retinoic acid combined with interferon-alfa effectively inhibits granulocyte–macrophage colony formation in chronic myeloid leukemia Leukemia Res 1996 20: 243–248
Garattini E, Mologni L, Ponzanelli I, Terao M . Cross-talk between retinoic acid and interferons: molecular mechanisms of interaction in acute promyelocytic leukemia cells Leuk Lymphoma 1998 30: 467–470.
Gordon MY . Plastic-adherent cells in human bone marrow generate long-term hematopoiesis in vitro Leukemia 1994 8: 865–870
Cornelissen JJ, Ploemacher RE, Wognum AW, Borsboom A, Kluin-Nelemans HC, Hagemeijer A, Lowenberg B . An in vitro model for cytogenetic conversion in CML: interferon-alpha preferentially inhibits outgrowth of malignant stem cells preserved in long-term culture J Clin Invest 1998 102: 976–983
Lindauer M, Domkin D, Dohner H, Kolb HJ, Neubauer A, Huhn D, Kreiter H, Koch B, Huber CH, Aulitzky W, Fischer T . Efficacy and toxicity of IFN-α2b combined with cytarabine in chronic myelogenous leukaemia Br J Haematol 1999 106: 1013–1019
Acknowledgements
This work was supported by the Leukaemia Research Fund of Great Britain.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Marley, S., Davidson, R., Goldman, J. et al. Combination of interferon alpha with either Ara-C or ATRA in vitro reduces the selective action of interferon against CML CFU-GM. Leukemia 14, 1396–1400 (2000). https://doi.org/10.1038/sj.leu.2401860
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2401860